BioCardia, Inc. (BCDA)
NASDAQ: BCDA · IEX Real-Time Price · USD
2.910
+0.030 (1.04%)
At close: Jul 19, 2024, 4:00 PM
2.850
-0.060 (-2.06%)
Pre-market: Jul 22, 2024, 7:12 AM EDT
BioCardia Revenue
BioCardia had revenue of $468.00K in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $55.00K. In the year 2023, BioCardia had annual revenue of $477.00K.
Revenue (ttm)
$468.00K
Revenue Growth
-65.49%
P/S Ratio
11.32
Revenue / Employee
$23,400
Employees
20
Market Cap
5.30M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
Dec 31, 2019 | 710.00K | 85.00K | 13.60% |
Dec 31, 2018 | 625.00K | 146.00K | 30.48% |
Dec 31, 2017 | 479.00K | -97.00K | -16.84% |
Dec 31, 2016 | 576.00K | -328.00K | -36.28% |
Dec 31, 2015 | 904.00K | 477.00K | 111.71% |
Dec 31, 2014 | 427.00K | 159.00K | 59.33% |
Dec 31, 2013 | 268.00K | 206.00K | 332.26% |
Dec 31, 2012 | 62.00K | 50.00K | 416.67% |
Dec 31, 2011 | 12.00K | - | - |
Dec 31, 2010 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBCDA News
- 5 days ago - BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application - GlobeNewsWire
- 6 weeks ago - BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach - GlobeNewsWire
- 2 months ago - BioCardia Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - BioCardia Reports First Quarter 2024 Business Highlights and Financial Results - GlobeNewsWire
- 2 months ago - BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 - GlobeNewsWire
- 2 months ago - BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes - GlobeNewsWire
- 3 months ago - BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort - GlobeNewsWire
- 4 months ago - BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results - GlobeNewsWire